Abstract
A new halogenated anthracycline analog 4′-deoxy-4′-iododoxorubicin (IODO) was compared with doxorubicin (DOX) and deoxydoxorubicin (DEOX) in the human tumor clonogenic assay (HTCA) using human tumor cell lines. For all cell lines tested, IODO had lower ID50 value and thus greater in vitro potency and cytotoxicity than DOX. DEOX had lower average ID50 values than either IODO or DOX in all cell lines except HEC1A, where DEOX was equal to IODO. Analysis of variance likewise confirmed significantly greater activity for IODO versus DOX in most cell lines tested. Previous in vivo studies demonstrate oral activity in a variety of tumors as well as less cardiotoxicity. Thus, the results of in vitro and in vivo studies suggest that IODO is an active compound of potential clinical interest.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F: Properties of antitumor anthracyclines and new developments in their application: Cain Memorial Award Lecture. Cancer Res 45:5995–5999, 1985
Barbieri B, Suarato A, Penco S, Geroni C, Bellini O, Fumagalli A, Casazza AM, Giuliani FC: Biologic activity of 4′-halo anthracyclines. (Abstr) Proc Amer Assoc Cancer Res 25:305, 1984
Barbieri B, Geroni C, Bellini O, Suarato A, Penco S, Giuliani FC: 4′-halo derivatives: A novel class of anthra-cyclines with interesting biologic properties. In: First European Conference on Advances in Antitumor Agents, Milan, May 30 to June 1, 1984, Proceedings. Milan: Associazione Farmaceutici Industrie
Barbieri B, Suarato A, Penco A, Giuliani FC, Geroni C, Casazza AM: Biologic properties of 4′-deoxy-4′doxorubicin. (Abstr) Invest New Drugs 2:120, 1984
Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461–463, 1977
Salmon SE, Hamburger AW, Soehnlen BJ, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human tumor stem cells to anticancer drugs. N Eng J Med 298:1321–1327, 1978
Salmon SE, Meyskens FL, Alberts DS, Soehnlen B, Young L: New drugs in ovarian cancer and malignant melanomas: In vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep 65:1–12, 1981
Salmon SE, Lie R, Casazza AM: Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemo Pharma 6:103–109, 1981
Salmon SE, Young L, Soehnlen B, Liu R: Antitumor activity of esorubicin in human tumor clonogenic assay with comparisons to doxorubicin. J Clin Oncol 2:282–286, 1984
Hamburger AW, Salmon SE, Kim MB, Trent JM, Soehnlen B, Alberts DS, Schmidt HJ: Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 38:3438–3443, 1978
Salmon SE, Young L, Lebowitz J, Thomson S, Einspahr J, Tong T, Moon TE: Evaluation of an automated image analysis system for counting human tumor colonies. Int J Cell Cloning 2:142–160, 1984
Neter J, Wasserman W, Kutner MH: Applied linear statistical models. Irwin: Homewood, Ill, p 721, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Schwartz, J.E., Salmon, S.E. Comparative in vitro activity of 4′-deoxy-4′-iododoxorubicin and other anthracyclines in the human tumor clonogenic assay. Invest New Drugs 5, 231–234 (1987). https://doi.org/10.1007/BF00175292
Issue Date:
DOI: https://doi.org/10.1007/BF00175292